| HRA002685
(Controlled Access)
|
Although TRK inhibitors have been approved for treating locally advanced or metastatic cancer patients with NTRK fusion, the prevalence, and genomic features of NTRK1/2/3 fusion in Chinese cancer patients have not been well elucidated. This study investigated the genomic context of NTRK fusion tumors using NGS in the largest Chinese real-world cohort to date. The present study also explored the utility of circulating tumor DNA in guiding the therapy of TRK inhibitors. |
